Status:
COMPLETED
Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis
Lead Sponsor:
University of North Carolina, Chapel Hill
Conditions:
ALS
Eligibility:
All Genders
18-99 years
Brief Summary
The purpose of this research study is to discover and quantitate the differences in post-translational modifications found in the Cu, Zn superoxide dismutase (SOD1) of patients with amyotrophic latera...
Detailed Description
Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease in which mutations in human Cu, Zn Superoxide Dismutase (SOD1) have been identified as a cause of familial ALS (FALS) cas...
Eligibility Criteria
Inclusion
- SALS patients
- SOD1 associated FALS patients
- Healthy control
Exclusion
- none
Key Trial Info
Start Date :
August 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 16 2018
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT02228915
Start Date
August 1 2014
End Date
October 16 2018
Last Update
October 17 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UNC Neurology ALS clinic
Chapel Hill, North Carolina, United States, 27599